Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report From the Children's Oncology Group

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-15-1349
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Antibody-Based Therapy of Acute Myeloid Leukemia With Gemtuzumab Ozogamicin

Frontiers in Bioscience - Landmark
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2013English

8-Chloro-Adenosine Activity in FLT3-ITD Acute Myeloid Leukemia

Journal of Cellular Physiology
Clinical BiochemistryCell BiologyPhysiology
2019English

Gemtuzumab Ozogamicin in Children With Relapsed or Refractory Acute Myeloid Leukemia: A Report of Berlin-Frankfurt-Münster Study Group

Haematologica
Hematology
2018English

DNA Damage on the DOCK in FLT3-ITD-driven Acute Myeloid Leukemia

Haematologica
Hematology
2019English

Targeting BTK for the Treatment of FLT3-ITD Mutated Acute Myeloid Leukemia

Scientific Reports
Multidisciplinary
2015English

Predictors and Short-Term Outcomes of Hyperleukocytosis in Children With Acute Myeloid Leukemia: A Report From the Children's Oncology Group

Haematologica
Hematology
2012English

The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia

Oncologist
Cancer ResearchMedicineOncology
2019English

High Dose Cytarabine Plus Gemtuzumab Ozogamicin for Patients With Relapsed or Refractory Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 19902

Leukemia Research
Cancer ResearchOncologyHematology
2011English

AAML0523: A Report From the Children's Oncology Group on the Efficacy of Clofarabine in Combination With Cytarabine in Pediatric Patients With Relapsed Acute Myeloid Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy